Helixate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the treatment of hemophilia A.
The most frequently reported adverse events were local injection-site reactions, dizziness, and rash.
Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Helixate® FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Helixate® FS.